1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,776 | 0,897 | 13.09. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| NFL BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| Di | NFL Biosciences to Present Its Personalized Medicine Approach to Smoking Cessation at the 20th Congress of the Société Francophone de Tabacologie | 275 | Business Wire | Oral presentation selected by the SFT 2026 dedicated to the predictive biomarker associated with NFL-101 efficacy in smoking cessation Presentation of the results of a post-hoc analysis... ► Artikel lesen | |
| 28.07. | NFL Biosciences submits phase 2 smoking cessation trial to regulators | 1 | Investing.com | ||
| 28.07. | NFL Biosciences Submits an Application for Authorization of the Phase 2 TONIC Clinical Trial Evaluating NFL-102 in Smoking Cessation | 428 | Business Wire | A Phase 2 clinical trial involving 310 smokers, designed to confirm the safety profile of NFL-102, determine its optimal dose, and evaluate its efficacy An adaptive design that allows for... ► Artikel lesen | |
| 07.07. | International Scientific Recognition for NFL Biosciences: 3 Presentations Selected at the 2026 SRNT-Europe Conference, Including an Oral Presentation on NFL-102 | 392 | Business Wire | Strengthening the international scientific recognition of NFL Biosciences' tobacco franchise within the leading scientific community dedicated to nicotine and tobacco research Oral presentation... ► Artikel lesen | |
| 30.06. | NFL Biosciences Announces the Successful Manufacturing of a GMP Clinical Batch of NFL-102 and Validates Its Industrial Production Chain | 387 | Business Wire | Validation of the entire GMP manufacturing chain for NFL-102, from extract production through to the lyophilized finished drug product Confirmation of NFL Biosciences' industrial capacity... ► Artikel lesen | |
| 01.06. | NFL Biosciences Releases New Results on NFL-101 and Reaffirms Its Personalized Approach to Smoking Cessation | 336 | Business Wire | Identification of a biomarker predictive of efficacy, enabling a personalized approach to smoking cessation with NFL-101 In the target population, efficacy approximately 30% higher than... ► Artikel lesen | |
| 25.05. | NFL Biosciences Is Strengthening Its Personalized Medicine Approach to Smoking Cessation With a New Patent Application | 594 | Business Wire | Personalized medicine approach that could represent a first in smoking cessation Biomarker rooted in NFL-101's immunomodulatory mechanism of action Rigorous analytical validation... ► Artikel lesen | |
| 11.05. | NFL Biosciences Clarifies the Objectives and Evaluation Criteria for a Predictive Biomarker Associated With NFL-101 | 348 | Business Wire | Regulatory News:
NFL BIOSCIENCES (Euronext Growth Paris FR0014003XT0 ALNFL, a biopharmaceutical company developing innovative botanical drugs for the treatment of addictions, today clarifies... ► Artikel lesen | |
| 04.05. | NFL Biosciences: International Scientific Community's Interest in NFL-102 for Smoking Cessation Confirmed by the Selection of Its Work at Two Leading Conferences | 411 | Business Wire | Regulatory News:
NFL BIOSCIENCES (Euronext Growth Paris FR0014003XT0 ALFNL), a biopharmaceutical company developing innovative botanical drugs for the treatment of addictions, announces that... ► Artikel lesen | |
| 15.04. | NFL Biosciences Presents Its 2025 Annual Results and Provides an Update on Its Clinical Progress Driven by a New Paradigm in Smoking Cessation | 535 | Business Wire | Emergence of a new paradigm in smoking cessation, based on an in-depth understanding of the biological mechanisms of addiction, with the ambition to achieve superior efficacy compared with current... ► Artikel lesen | |
| 15.04. | NFL Biosciences Strengthens Its Cash Position by €2.6 Million Through Bond Financing Subscribed by a Group of European Institutional Investors | 573 | Business Wire | A €2.6 million bond financing has been secured with a group of European investors including Vester Finance, a shareholder of the Company Cash runway is immediately extended until the third... ► Artikel lesen | |
| 07.04. | A New Paradigm in Tobacco and Nicotine Addiction: NFL Biosciences Demonstrates the Mechanism of Action of NFL-102 in a Video | 388 | Business Wire | A breakthrough mechanism of action targeting neural plasticity associated with addiction, particularly through the CREB regulator, a key factor in relapse An educational video illustrating... ► Artikel lesen | |
| 11.03. | Bpifrance Renews Its Confidence in NFL Biosciences Through the Granting of a €500,000 Loan | 570 | Business Wire | €500,000 loan with a 36-month repayment deferral Financial support to prepare the submission of the Phase 2 clinical trial application for NFL-102 expected in mid-2026 Strengthening... ► Artikel lesen | |
| 19.02. | NFL Biosciences Publishes Its 2026 Financial Agenda | 458 | Business Wire | Regulatory News:
NFL BIOSCIENCES (Euronext Growth Paris FR0014003XT0 ALFNL), a biopharmaceutical company developing botanical drugs for the treatment of addictions, presents its financial agenda... ► Artikel lesen | |
| 26.01. | NFL Biosciences SA: NFL Biosciences Significantly Raises Its Efficacy Targets for Smoking Cessation | 441 | Business Wire | In-depth understanding of the mechanism of action of its drug candidates based on new data Enhanced clinical development strategy based on these advances, targeting clinical efficiencies... ► Artikel lesen | |
| 08.12.25 | NFL Biosciences Obtains Complementary Characterization Results for NFL-101, its first-in-class Drug Candidate for Smoking Cessation, and Prepares a New Patent Application | 390 | Business Wire | These results represent the first scientific milestone expected by regulatory agencies and potential pharmaceutical partners New patent application currently in preparation Results... ► Artikel lesen | |
| 12.11.25 | NFL Biosciences SA: NFL Biosciences Presents the Agenda for Results Expected by Regulatory Agencies and Potential Pharmaceutical Partners | 472 | Business Wire | Regulatory News:
NFL Biosciences SA (Euronext Growth Paris FR0014003XT0 ALNFL), a biopharmaceutical company developing innovative botanical drugs for the treatment of addiction, today presents... ► Artikel lesen | |
| 20.10.25 | NFL Biosciences Outlines Its Development Plan for NFL-101 in Smoking Cessation Following Receipt of Scientific Advice From Several European Agencies and the U.S. FDA | 544 | Business Wire | Confirmation by several European agencies and the U.S. FDA of the relevance of the continuous abstinence validation criteria which showed statistical significance (p=0.02) in the Phase 2 CESTO... ► Artikel lesen | |
| 16.10.25 | NFL Biosciences Reports Its 2025 Half-Year Results and Provides an Update on Its Development | 672 | Business Wire | Additional studies and analyses confirming the excellent safety profile of NFL-101, its immunological action associated with smoking abstinence, and its rapid and sustained effects on brain regions... ► Artikel lesen |
19 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SUMMIT THERAPEUTICS | 17,550 | 0,00 % | Mercks 30-Milliarden-Dollar-Blockbuster bekommt neue Konkurrenz - warum Big Pharma schon die nächste Plattform sucht | ||
| TANGO THERAPEUTICS | 23,780 | 0,00 % | Tango Therapeutics, Inc.: Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights | Company continues to prepare for late-stage clinical advancement of vopimetostat in combination with daraxonrasib for pancreatic cancer following positive Phase 1/2 data Phase 1/2 data from combination... ► Artikel lesen | |
| RELAY THERAPEUTICS | 18,870 | 0,00 % | Relay Therapeutics: Zovegalisib-Pipeline steht vor entscheidenden Meilensteinen | ||
| VERA THERAPEUTICS | 35,090 | +0,11 % | Vera Therapeutics: Erfolgreicher Start für Nierenmedikament TRUTAKNA | ||
| QIAGEN | 36,525 | -0,25 % | BERENBERG stuft QIAGEN NV auf 'Hold' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat Qiagen mit einem Kursziel von 40 Euro auf "Hold" belassen. Der Medizintechnik- und Life-Science-Sektor bleibe fundamental attraktiv, wie die... ► Artikel lesen | |
| DYNE THERAPEUTICS | 18,230 | +0,11 % | Aktien New York Ausblick: Dow schwächelt weiter - Nasdaq stabil erwartet | NEW YORK (dpa-AFX) - Die US-Börsen steuern nach dem verlängerten Wochenende am Dienstag auf eine durchwachsene Eröffnung zu. Auf die Stimmung drückten die weiter steigenden Ölpreise, die der Angst... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 44,450 | +0,11 % | Edgewise Therapeutics Reports Second Quarter 2026 Financial Results | - Announced positive top-line data from 12-week Phase 2 CIRRUS-HCM trial with EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy (HCM) -
- ... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 79,31 | 0,00 % | Jefferies erhöht Kursziel für Tarsus Pharmaceuticals nach Prognoseanhebung | ||
| ARCUTIS BIOTHERAPEUTICS | 23,880 | -0,02 % | Arcutis Biotherapeutics, Inc.: Arcutis Expands Board of Directors with Appointment of Chris Peetz | WESTLAKE VILLAGE, Calif., July 16, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovation in... ► Artikel lesen | |
| COGENT BIOSCIENCES | 33,410 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM) | Submission based on results of APEX pivotal trial which demonstrated bezuclastinib objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria with a well-tolerated... ► Artikel lesen | |
| ERASCA | 15,890 | 0,00 % | Erasca, Inc.: Erasca Reports Second Quarter 2026 Business Updates and Financial Results | Updated ERAS-0015 data in U.S. trial highlighted compelling monotherapy efficacy in 2L+ KRAS G12X PDAC and continued favorable tolerability, as well as further advancement of panitumumab CRC combination... ► Artikel lesen | |
| ARCUS BIOSCIENCES | 24,570 | 0,00 % | Arcus Biosciences: Casdatifan-Strategie auf der Cantor Global Healthcare Conference im Fokus | ||
| IMMUNOVANT | 37,330 | -0,08 % | Immunovant Inc.: Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 | IMVT-1402 showed clinically meaningful response rates of 72.7% ACR20, 54.5% ACR50 and 35.8% ACR70 at Week 16 in the open label period of its trial in difficult-to-treat rheumatoid arthritis (D2T RA)... ► Artikel lesen | |
| CANDEL THERAPEUTICS | 10,545 | 0,00 % | Candel Therapeutics Appoints Martine Zimmermann, PharmD, to its Board of Directors | Regulatory and quality expertise strengthens Board as Candel advances toward planned Biologics License Application (BLA) submission and potential commercial readiness NEEDHAM, Mass., Sept. 10, 2026... ► Artikel lesen | |
| MODERNA | 124,98 | +0,68 % | Moderna-Aktie bei 144 US$: Nächstes Hoch in Sicht? | Die Moderna-Aktie konnte gestern um +5,38% zulegen, nachdem der Kurs zuvor rund -34% korrigiert hatte. Damit zeigt sich nach dem deutlichen Rücksetzer eine erste Gegenbewegung. Nun stellt sich die entscheidende... ► Artikel lesen |
NFL BIOSCIENCES SA gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,773 Euro und damit -2,28 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NFL BIOSCIENCES SA finden Sie auf Wallstreet Online.